UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT...
Filed pursuant to Rule 424(b)(5) Registration No. 333-252664 Prospectus Supplement (To Prospectus...
As filed with the Securities and Exchange Commission on March 15, 2022 Registration No. 333- [●] UNITED...
TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- Β China SXT Pharmaceuticals, Inc. ("SXTC" or the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
Filed pursuant to Rule 424(b)(5) Registration No. 333-252664 Prospectus Supplement...
TAIZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company...
TAIZHOU, China, Jan. 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company...
Filed pursuant to Rule 424(b)(5) Registration No. 333-252664 The information in...
TAIZHOU, China, Jan. 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company...
China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads